Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sparfloxacin: a review.

J J Schentag1

  • 1The Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Kaleida Health, Buffalo, New York 14209, USA.

Clinical Therapeutics
|May 24, 2000
PubMed
Summary
This summary is machine-generated.

Sparfloxacin, an oral fluoroquinolone, shows efficacy and a similar safety profile to macrolides for treating community-acquired pneumonia (CAP) and acute bacterial exacerbations of chronic bronchitis (ABECB). This makes it a valuable option against resistant respiratory pathogens.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of organism species on microbial eradication and development of resistance in severe gram-negative pneumonia.

Journal of chemotherapy (Florence, Italy)·2010
Same author

A case series of macrolide treatment failures in community acquired pneumonia.

Journal of chemotherapy (Florence, Italy)·2007
Same author

Pharmacokinetic and pharmacodynamic modelling of antibiotic therapy.

Current opinion in infectious diseases·2006
Same author

Linezolid in the treatment of osteomyelitis: results of compassionate use experience.

Infection·2004
Same author

Pharmacokinetics and metabolism of moxifloxacin.

Drugs of today (Barcelona, Spain : 1998)·2003
Same author

Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia.

Annals of oncology : official journal of the European Society for Medical Oncology·2003
Same journal

Early Feasibility Studies in Europe: A Multisite Qualitative Study of Operational Challenges and Site Selection Determinants at 6 University Hospitals.

Clinical therapeutics·2026
Same journal

Safety of Celecoxib in Elderly Patients With Osteoarthritis: A Real-World Analysis Based on the FAERS Database.

Clinical therapeutics·2026
Same journal

Reimagining Representation Across the Clinical Research Ecosystem: Part II of a Specialty Update on Advancing Diversity, Racial Equity, and Inclusion in Clinical Research.

Clinical therapeutics·2026
Same journal

Combined Effects of Nicorandil and Enhanced External Counterpulsation on Coronary Microcirculation and Exercise Capacity in Patients With Coronary Slow Flow Phenomenon: A Randomized, Controlled, 3-Arm Trial.

Clinical therapeutics·2026
Same journal

Phase 1 Study Evaluating Gefurulimab Pharmacokinetics and Safety Following Delivery Via Autoinjector or Prefilled Syringe With Needle Safety Device in Healthy Adults.

Clinical therapeutics·2026
Same journal

Evaluating Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Associated With Newer Antiseizure Medications Using FAERS and JADER Combined With Bioinformatics Exploration.

Clinical therapeutics·2026
See all related articles

Area of Science:

  • Pharmacology and Microbiology
  • Infectious Diseases
  • Respiratory Medicine

Background:

  • Increasing resistance to penicillin, cephalosporins, and macrolides necessitates alternative treatments for respiratory infections.
  • Fluoroquinolone antibiotics are recommended for high-risk patients with community-acquired pneumonia (CAP) and acute bacterial exacerbations of chronic bronchitis (ABECB).

Purpose of the Study:

  • To review sparfloxacin, an oral fluoroquinolone, focusing on its mechanism of action, antimicrobial activity, pharmacokinetics, safety, and clinical efficacy.
  • To evaluate sparfloxacin's role in treating CAP and ABECB, particularly in the context of rising antibiotic resistance.

Main Methods:

  • Literature search of MEDLINE from 1990 to 1999.
  • Inclusion of supplementary educational materials from conferences and symposia.

Related Experiment Videos

Main Results:

  • Sparfloxacin demonstrates activity against major respiratory pathogens and atypical pneumonia pathogens.
  • Its long half-life allows for once-daily dosing, improving patient compliance.
  • Clinical trials indicate sparfloxacin has comparable efficacy to erythromycin, cefaclor, amoxicillin, ofloxacin, and clarithromycin in CAP and ABECB, with a similar safety profile to macrolides and other quinolones. Common adverse events include photosensitivity, nausea, and diarrhea; contraindicated in QTc prolongation.

Conclusions:

  • The rise of beta-lactam and macrolide resistance in respiratory infections highlights the importance of newer agents like fluoroquinolones.
  • Treatment decisions for high-risk patients should prioritize agents with proven activity against prevalent respiratory pathogens.